Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy.
Dapsone is widely used in dermatological practice. The case of a Greek female patient is reported who had a severe, acute, haemolytic episode shortly after commencing dapsone therapy, despite a normal glucose-6-phosphate dehydrogenase (G6PD) screening test. A subsequent quantitative assay revealed reduced levels of G6PD consistent with the heterozygous state. This illustrates that routine screening tests may fail to detect the decreased levels of (G6PD) which occur in female heterozygotes. Since these patients are at risk of severe dapsone-induced haemolysis, the need for quantitative G6PD assays in females from susceptible racial groups is emphasized.
Todd
P
P
Department of Dermatology, King's College Hospital, London, UK.
Samaratunga
I R
IR
Pembroke
A
A
D000293:Adolescent; D000743:Anemia, Hemolytic / Q000139:chemically induced; D000075202:Contraindications; D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications / Q000175:diagnosis*; D006801:Humans; D017514:Pityriasis Lichenoides / Q000150:complications / Q000188:drug therapy
D003622:Dapsone